Bookmark or Share 
Print 
|
RSS
Bookmark or Share
Print
|
Oncology |
||
| Anti-Tumour Agents | 10628 | A novel class of compounds for BNCT of tumours and for PET imaging, with potential for increased selectivity towards tumour cells and for tumours in the CNS. |
| Lead Series Targeting Cancer | 9331 | A novel lead series of Platinum-based (or Palladium/copper) reversible DNA-intercalating agents with excellent potency and low in vivo toxicity. |
Central Nervous System (CNS) |
||
| Compounds Targeting Anxiety Related Disorders and Depression | 10981 | A novel class of P2X antagonist for the treatment of CNS disorders and neuropathic pain. |
| Ligands for the Translocator Protein (18 kDa) (TSPO) | 10459 | Novel lead series of ligands for the Translocator Protein (18 kDa) for treatment of neurodegenerative disorders and neuroinflammation. |
Other Therapeutics |
||
| Compounds for the Treatment of Iron Overload Disease | 11008 | Novel compounds have been designed to treat iron-overload disease that have superior pharmacological properties to current drugs. |
| Prevention of Neurotropic Virus Transport | 11880 | Novel antiviral target based on preventing transport of herpes simplex virus within a nerve cell. |
| Novel Anti-Fungal Agents | 10460 | Two novel classes of anti-fungal agents that have demonstrated broad spectrum of activity against fungal species with significantly improved properties over existing antifungal compounds |
| Anti-Bacterials Targeting Periodontal Disease | 9989 | A novel target and associated lead series for the treatment of periodontal disease. |
Diagnostics |
||
| Diagnostic test for the Prediction of Response to Pegylated Interferon Alpha | 12342 | We have identified a set of single nucleotide polymorphisms (SNPs) to predict response to pegylated interferon alpha treatment for hepatitis C. This set of SNPs form the basis of a genetic test kit for the prediction of antiviral therapy using interferon alpha, and for other uses of interferon. |
| Rapid Tests for Disease Diagnoses | 12112 | The technology requires a drop of biological fluid, such as blood, from which fast and accurate pathology tests can be used to indicate the presence of certain specific diseases before clinical signs are apparent, or to differentiate diseases with similar clinical symptoms. |
| A Novel Method for the Quantitative Detection of Microorganisms | 5733 | An innovative and rapid approach to the quantitative and qualitative determination of bacterial load in any sample. |
| Novel Diagnostic Markers for Transmissible Pseudomonas Aeruginosa | 11045 | A diagnostic method for identifying transmissible Pseudomonas aeruginosa. |
| Diagnosis of Latent Phase in Cytomegaloviral Infections | 6453 | A method of identifying latent phase Cytomegaloviral infections. |
Platform Technologies |
||
| Peptide Ligation | 12268 | A novel ligation method for the synthesis of phosphopeptides and peptides, using serine or threonine residues to facilitate amide bond formation with a range of C-terminal thioesters. |
| High Expression System For Human Lysyl Oxidase | 12128 | An over expression system that provides for the efficient production of large amounts of the human lysyl oxidase protein. |
| Covalent Attachment of Bioactive Protein to Any Surface | 10132 | This technology enables the robust attachment of biomolecules, including enzymes, antibodies, structural proteins and synthetic polypeptides, to any underlying material, retaining biological activity. |
| Drug Screen for Anti-Malaria and other Anti-Parasitic Drugs | 11066 | A new phylum of easily cultured algae that can be used to develop and screen drugs that target apicoplasts, a known target for antiparasitic drugs. |
| Detection of HIV biogenesis | 11165 | REDOX sensitive method that can resolve detection of active replicating HIV to the cytosol of the infected cell. |
| Encapsulated Catalyst | 10625 | A method for placing various catalysts in nanocapsules, which protects the catalysts from harmful conditions and facilitates their recovery from reaction mixtures. |
| Demibodies | 5871 | A novel structural group of human chimeric antibodies that selectively kill diseased cells that express unique combinations of surface markers, similar to Domantis’ dual-targeting domain antibody (dAb) approach. |
| Novel Proteinases: Dipeptidyl Peptidases 8 and 9 (DPP8 and DPP9) | 10578 | Two new enzymes (DPP8 and DPP9) cloned and sequenced with multiple applications, including, selectivity screening of DPP-IV inhibitors. |
Tissue Engineering and Drug Delivery |
||
| Baghdadite - Ca3ZrSi2O9, A Biocompatible Ceramic | 12220 | A novel calcium zirconium silicate-based ceramic that has enhanced mechanical strength, osteoconductive & osteoinductive properties, and decreased solubility. |
| Strontium Modified Hardystonite - Sr-Ca2ZnSi2O7, A Biocompatible Ceramic | 11453 | A new material combining bioactive Zn and Sr ions in the Ca-SiO3 system by partly replacing Ca ions in Hardystonite by sol-gel method. The new material will further enhance the biological properties. |
| Tissue Engineering and Local Drug Delivery | 10631 | A method for producing microporous polymer matrices with very high loadings of bioactive molecules. Applications include tissue engineering scaffolds and inserts for local drug delivery. |
| Carriers for Dry Powder Inhalation Drug Delivery | 10632 | A new approach for producing carriers which can be tailored to different drugs enabling highly efficient aerosolisation performance and improved content uniformity. |
| Nano-particle Drug Delivery | 10103 | Technology for manufacture of nanoparticles (and coated nanoparticles) from 10nm in diameter suitable for drug delivery. |
Animal Health |
||
| Genetic Markers for Fibre Pigmentation in Animals | 10614 | A technology to use genetic markers to identify animals susceptible to producing dark hair or wool fibres. The technology is particularly suited to sheep. |
| Equine Performance Test | 10615 | Genetic markers used to indicate the health and determine the physical performance of a horse. |
| Mycobacterium Antigens, Diagnostics and Vaccines | 11020 | A range of Mycobacterium paratuberculosis proteins that are expressed during a stress response in the host can be used as targets for diagnosis of mycobacterial infection. |